Bortezomib. Market analysis

Nature Reviews Drug Discovery

Volumn 2, Issue 8, 2003, Pages 611-612

  Paramore, Andrew ^a   Frantz, Simon ^b  

^a Decision Resources Intl   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CC 394; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LENALIDOMIDE; MELPHALAN; OBLIMERSEN; PREDNISONE; PROTEINASE INHIBITOR; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

CANCER RECURRENCE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIPLE MYELOMA; NOTE; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTOPENIA; ARTICLE; DRUG INDUSTRY; ECONOMICS; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PYRAZINES; TREATMENT OUTCOME; UNITED STATES;

EID: 0042568690     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1159     Document Type: Note

References (12)

1. Coux, O., Tanaka, K. & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801-847 (1996).
2. King, R. W., Deshaies, R. J., Peters, J.-M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652-1659 (1996).
3. Kisslev, A. F. & Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 121, 1-20 (2001).
4. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076 (2001).
5. Barnes, P. J. & Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071 (1997).
6. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785 (1994).
7. Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 28, 613-619 (2001).
8. Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338 (1998).
9. Anderson, P. G. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
10. FDA Drug Approvals List [online] (cited 13 May 2003) http:// www.fda.gov/cder/foi/label/2003/021602lbl.pdf (2003).
11. Zangari, M. et al. Marked activity also in Del 13 multiple myeloma (MM) of PS-341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. Proc. Am. Soc. Hematol. A387 (2002).
12. Orlowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, Valcade™) in combination with pegylated liposomal doxorubicin (Doxil™) in patients with refractory hematological malignancies. Proc. Am. Soc. Hematol. A388